Psilera Inc. has announced animal findings for its first cohort of drug candidates designed and synthesized in-house showing that they are non-hallucinogenic. This group includes six patent-pending compounds with novel structural features across four compound families.
By using a statin to preferentially increase the expression of HER2 on tumor cells, researchers at Memorial Sloan Kettering were able to sensitize gastric cancers to a HER2-targeted radioligand in animal models of gastric cancer. Lovastatin aided the radioligand via two distinct mechanisms. First, it increased the availability of HER2 on the cell surface, allowing greater binding. It also had radioprotective effects on normal cells, reducing the toxicity of higher doses of radiation.
Scientists from the UK Dementia Research Institute at the University of Cambridge have described how cytosolic antibody receptor TRIM21 contributes to in vivo protection during tau immunotherapy. Their work on TRIM21’s mechanism of action may help in moving a step closer toward enhanced second-generation antibodies for tauopathy treatments.
A research team based at MIT and Harvard has engineered a bacterial injection system to precisely deliver proteins to human cells. This work, published online March 29, 2023, in Nature, is important as while more and more molecular therapies are being developed, off-target effects are always a concern and precise targeting of cells and tissues can still be a challenge.
Cholesgen (Shanghai) Co. Ltd. has prepared and tested tricyclic diterpene analogues acting as Hedgehog (Hh) signaling inhibitors and apoptosis inducers. As such, they are reported to be useful for the treatment of cancer.
RSS
